MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS
The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
1 . A method of producing a polypeptide of interest in a mammalian cell or tissue, the method comprising, contacting said mammalian cell or tissue with a formulation comprising a modified mRNA encoding the polypeptide of interest, wherein the formulation is selected from the group consisting of nanoparticles, poly(lactic-co-glycolic acid) (PLGA) microspheres, lipidoid, lipoplex, liposome, polymers, carbohydrates (including simple sugars), cationic lipids, fibrin gel, fibrin hydrogel, fibrin glue, fibrin sealant, fibrinogen, thrombin, rapidly eliminated lipid nanoparticles (reLNPs) and combinations thereof.
2 . The method of claim 1 , wherein the modified mRNA comprises a purified IVT transcript.
3 . The method of claim 1 , wherein the formulation comprising the modified mRNA is a nanoparticle and wherein said nanoparticle comprises at least one lipid.
4 . The method of claim 3 , wherein the lipid is selected from the group consisting of DLin-DMA, DLin-K-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG and PEGylated lipids.
5 . The method of claim 3 , wherein the lipid is cationic lipid.
6 . The method of claim 5 , wherein the cationic lipid is selected from the group consisting of DLin-DMA, DLin-K-DMA, DLin-MC3-DMA, DLin-KC2-DMA and DODMA.
7 . The method of claim 3 , wherein the lipid to modified mRNA weight ratio is between 10:1, and 30:1.
8 . The method of claim 7 , wherein the mean size of the nanoparticle formulation comprising the modified mRNA is between 60-225 nm.
9 . The method of claim 8 , wherein the PDI of the nanoparticle formulation comprising the modified mRNA is between 0.03 and 0.15.
10 . The method of claim 3 , wherein the zeta potential of the lipid is from −10 to +10 at a pH of 7.4.
11 . The method of claim 7 , wherein the nanoparticle formulation comprising the modified mRNA further comprises a fusogenic lipid, cholesterol, and a PEG lipid.
12 . The method of claim 11 , wherein the nanoparticle formulation comprising the modified mRNA has a molar ratio of 50:10:38.5:1.5-3.0 (Cationic Lipid: fusogenic lipid: Cholesterol: PEG lipid).
13 . The method of claim 12 , wherein the PEG lipid is selected from PEG-c-DOMG and PEG-DMG and the fusogenic lipid is DSPC.
14 . The method of claim 1 , wherein contacting is through the use of a device selected from the group consisting of syringe pump, internal osmotic pump and external osmotic pump.
15 . The method of claim 1 , wherein the formulation comprising the modified mRNA is a poly(lactic-co-glycolic acid) (PLGA) microsphere.
16 . The method of claim 15 , wherein microspheres of the PLGA microsphere formulation comprising the modified mRNA are between 4 and 20 μm in size.
17 . The method of claim 15 , wherein the PLGA microsphere formulation comprising the modified mRNA release less than 50% of the modified mRNA in a 48 hour time period.
18 . The method of claim 15 , wherein the PLGA microsphere formulation comprising the modified mRNA is stable in serum.
19 . The method of claim 18 , wherein the stability is determined relative to unformulated modified mRNA in 90% serum.
20 . The method of claim 15 , wherein the loading weight percent is at least 0.05%, at least 0.1%, at least 0.2%, at least 0.3%, or at least 0.4%.
21 - 54 . (canceled)